[Clinical studies conducted with a new epinephrine derivative for the treatment of glaucoma (Dipivalyl epinephrine)].
Dipivalyl epinephrine, an epinephrine derivative, has been developed to improve the pharmacokinetic properties of the compound. Our open-label investigation included the administration of dipivalyl epinephrine ophthalmic solution to the eyes of 33 patients with an open-angle glaucoma. Former topical medication of parasympathomimetic agents was continued. The 0.1% dipivalyl epinephrine treatment approximated the results obtained with 1% epinephrine borate or phenylephrine 5% in reducing the intraocular pressure.
D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004361:Drug Tolerance; D004837:Epinephrine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D013566:Sympathomimetics / Q000627:therapeutic use*; D014785:Vision, Ocular / Q000187:drug effects
D013566:Sympathomimetics; D004837:Epinephrine
Erfahrungen mit einem neuen Adrenalinpräparat in der Glaukomtherapie (Dipivalyl-Epinephrin).